How does Jeuveau market share compare to Botox and Dysport?

Jeuveau holds the third position in the toxin market behind Botox (Allergan Aesthetics) and Dysport (Galderma). Evolus has gained traction among independent practices by positioning aggressive Aspire rebates as an alternative to AbbVie's Alle ecosystem, but remains the smaller player in overall market penetration.

What does Jeuveau's Q2 2023 earnings data tell practitioners about rebate strategy?

Evolus' Q2 results show that rebate depth and practitioner loyalty drive market share more than clinical differentiation. Practices evaluating Jeuveau should focus on comparing Aspire rebate programs against competitor offers rather than relying on onset speed or diffusion profile as primary decision factors.

Should I stock Jeuveau if I'm already using Botox or Dysport?

Q2 2023 data suggests Jeuveau makes economic sense primarily for independent practices seeking to reduce reliance on AbbVie's Alle ecosystem. Benchmark your own Jeuveau utilization against market averages to determine whether the rebate economics justify inventory commitment alongside existing toxin suppliers.

What is Jeuveau's competitive advantage in the toxin market?

Jeuveau's primary advantage is aggressive Aspire rebate positioning targeted at independent practices, not clinical differentiation. The toxin's onset speed and diffusion profile matter less than rebate depth when practitioners are deciding between the three major toxins.

How can practices use Evolus Q2 earnings to evaluate their toxin supply chain?

Use the Q2 revenue breakdown to assess Jeuveau's market traction and stability as a long-term supplier option. Compare Jeuveau's rebate programs and economics against Botox and Dysport offerings to determine whether diversifying your toxin portfolio aligns with your practice's profitability goals.

Monday, August 24, 2026 Never miss a recall or a rule change Go Pro · $20/mo →

RegulatoryAbbVie Launches Phase 2 Forehead Lines Studytoday MarketFacial Rejuvenation Market Forecast to Hit $5.66B by 20302 days ago Business & M&AAllergan Aesthetics Overhauls Loyalty Programtoday Devices & TechXERF Technology Enters Australian Market for Skin Tightening2 days ago Business & M&AEvolus Expands Estyme to Canada, Australia, New Zealandtoday MarketArm Fat Now Top Body Sculpting Concern in Singapore2 days ago Devices & TechSofwave Hits One Million Treatments Milestonetoday RegulatoryCKD Bio Pursues China Botox Approval—2027 Launch Targeted2 days ago RegulatoryRevance Wins FDA Nod for Under-Eye Injectablesyesterday MarketGLP-1 Pill Era Is Forcing Beauty Market Shiftyesterday InjectablesAEON Releases Expanded ABP-450 Botox Biosimilar Datayesterday Devices & TechUltherapy PRIME Real-Time Imaging Reshapes Midface Liftingyesterday

Injectables

Evolus Q2 2023: Revenue Breakdown Signals Jeuveau Stabilization

Toxin maker's earnings reveal where Jeuveau stands against Botox and Dysport in competitive market.

By Evan at Inside MedSpa · Jul 30, 2026

1-YEAR MOVE

EOLS ▼15.6% ABBV ▲11.6%

1-year price move by ticker
Ticker	Company	1-year change
EOLS	Evolus	−15.6%
ABBV	AbbVie (Allergan Aesthetics)	+11.6%

Evolus, Inc. released its Q2 2023 earnings report, providing granular revenue breakdown data that illuminates Jeuveau's market position relative to Allergan Aesthetics' Botox and Galderma's Dysport. The filing offers practitioners a window into how the third-major toxin is tracking in the competitive landscape—critical for practices evaluating rebate programs and supply-chain partnerships.

Inside MedSpa Pro

You've reached your free articles this week.

Keep reading every article, unlock the full trackers, and get the twice-a-week intelligence brief — from $20/mo, or $200/yr (two months free). Never miss a recall or a rule change.

Every article, unlocked — no weekly limit
The full 50-state law tracker, stock & M&A watch
The twice-a-week, 2-minute intelligence brief
Recalls, FDA clearances & safety signals as they hit

See everything you get →

Cancel anytime, one click · 14-day money-back on annual

https://insidemedspa.com/article/evolus-eols-revenue-breakdown-q2-2023/

Discussion

Free alerts

Get flagged before it costs you.

We'll flag the moment a recall or rule change hits your practice. One email a week, one click to leave.

Free · weekly · unsubscribe anytime. Privacy.

This morning's brief · 6 AM

The free version stops here.

What today's moves mean for your margins — and exactly what to do — already went out to Pro. By the time the trade press explains it, the window to act has closed.

Go Pro · $20/mo Two minutes a morning. Cancel anytime.

Live · Market movers

STRATA Skin Sciences-50%Hims & Hers Health+6.03%Estée Lauder+6.02%Bausch Health (Solta)-5.43%The Beauty Health Company (HydraFacial)+3.65%

The full stock & M&A watch →

FDA Activity — Aesthetic Devices

Monthly 510(k) clearances vs. recalls.

510(k) clearances Recalls

FDA Activity — Aesthetic Devices — Monthly 510(k) clearances vs. recalls.
Month	510(k) clearances	Recalls
Jun '25	0	4
Jul '25	0	1
Sep '25	0	1
Oct '25	0	2
Jan '26	0	1
Feb '26	0	5
Mar '26	0	5
Apr '26	0	19
May '26	7	18
Jun '26	34	8
Jul '26	23	4
Aug '26	5	0

The 50-state regulation tracker →

Inside MedSpa Pro

By the time it's news, it's too late.

The rebate cut, the scope-of-practice bill, the competitor opening down the street — it hits your business before the trade press ever covers it. Pro gets you there first: what happened, why it touches your margins, and exactly what to do — at 6 AM, in two minutes.

Go Pro · $20/mo Never miss a recall or a rule change. Cancel anytime.

The twice-a-week intelligence brief Go Pro · $20/mo →

Evolus Q2 2023: Revenue Breakdown Signals Jeuveau Stabilization

Share

Discussion

Leave a comment

By the time it's news, it's too late.